Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 112 participants.

Also called NCT01135017

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 112 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01135017
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01135017. Randomized; triple masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-02 (actual). Results posted on 2013-04-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers
Acronym
HESTIA
Intervention (Drug)
Dronedarone
Intervention (Drug)
Placebo (for Dronedarone)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01135017
Content hash
e233a2f06f7392f1ab72fedb94056ad94924a135136318d5b93f6ad742fddf09